High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma

Journal of Hematology and Oncology

Volumn 4, Issue , 2011, Pages

  Zl, Wu ^a   Yq, Song ^a   Yf, Shi ^a   Zhu, J ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; RITUXIMAB; STAT3 PROTEIN; VINCRISTINE;

ADULT; ARTICLE; CANCER SURVIVAL; CELL NUCLEUS; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 80052229391     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-4-31     Document Type: Article

References (29)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, (Eds), World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008
2. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Harris N L, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Blood 1994 84 5 1361 1392 8068936 (Pubitemid 24273002)
3. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM, Blood 2007 109 5 1857 1861 10.1182/blood-2006-08-038257 17105812 (Pubitemid 46348180)
4. Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI). Talaulikar D, Shadbolt B, Dahlstrom JE, McDonald A, J Hematol Oncol 2009 22;2 49 21645367
5. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Alizadeh A A, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM, Nature 2000 403 503 11 10.1038/35000501 10676951 (Pubitemid 30082188)
6. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lápez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM, Lymphoma/Leukemia Molecular Profiling Project, N Engl J Med 2002 346 25 1937 47 10.1056/NEJMoa012914 12075054 (Pubitemid 34651353)
7. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM, Proc Natl Acad Sci USA 2003 100 17 9991 6 10.1073/pnas.1732008100 12900505 (Pubitemid 37087056)
8. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lápez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, MabThera International Trial Group, Lancet Oncol 2006 7 5 379 91 10.1016/S1470-2045(06)70664-7 16648042
9. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. Sehn L H, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O'Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM, J Clin Oncol 2005 23 22 5027 33 10.1200/JCO.2005.09.137 15955905 (Pubitemid 46224009)
10. STAT proteins: from normal control of cellular events to tumorigenesis. Calo' V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, Russo A, J Cell Physiol 2003 197 157 168 10.1002/jcp.10364 14502555 (Pubitemid 37485244)
11. STAT3: a critical transcription activator in angiogenesis. Chen Z, Han ZC, Med Res Rev 2008 28 2 185 200 10.1002/med.20101 17457812 (Pubitemid 351281185)
12. ABT-869, a promising multi-targeted tyrosine kinase inhibitor:from bench to bedside. Zhou Jianbiao, Goh Boon-Cher, Daniel Albert H, Chen Shing Chien, J Hematol Oncol 2009 2 33 46 10.1186/1756-8722-2-33 19642998
13. Targeted therapy of lymphoma. Patrick Johnston B, Yuan RuiRong, Cavalli Franco, Thomas Witzig E, J Hematol Oncol 2010 3 45 10.1186/1756-8722-3-45 21092307
14. STAT proteins as novel targets for cancer drug discovery. Turkson J, Expert Opin Ther Targets 2004 8 5 409 22 10.1517/14728222.8.5.409 15469392 (Pubitemid 39359648)
15. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-B pathways in subtypes of diffuse large B-cell lymphoma. Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, Chan JW, Rosenwald A, Gascoyne RD, Staudt LM, Blood 2008 111 7 3701 13 10.1182/blood-2007-09-111948 18160665
16. STAT3 Inhibition Is a Therapeutic Strategy for ABC-like Diffuse Large B-Cell Lymphoma. Scuto A, Kujawski M, Kowolik C, Krymskaya L, Wang L, Weiss LM, Digiusto D, Yu H, Forman S, Jove R, Cancer Res 2011 71 9 3182 8 10.1158/0008-5472.CAN-10-2380 21521803
17. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, Zhang Y, Cattoretti G, Ye BH, Blood 2008 111 3 1515 23 17951530 (Pubitemid 351213441)
18. Janus kinases: components of multiple signaling pathways. Rane SG, Reddy EP, Oncogene 2000 19 49 5662 79 10.1038/sj.onc.1203925 11114747
19. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Dechow T N, Pedranzini L, Leitch A, Leslie K, Gerald WL, Linkov I, Bromberg JF, Proc Natl Acad Sci USA 2004 101 29 10602 7 10.1073/pnas.0404100101 15249664 (Pubitemid 38955788)
20. Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. Baran-Marszak F, Boukhiar M, Harel S, Laguillier C, Roger C, Gressin R, Martin A, Fagard R, Varin-Blank N, Ajchenbaum-Cymbalista F, Ledoux D, Haematologica 2010 95 11 1865 72 10.3324/haematol.2009.019745 20663948
21. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Niu Guilian, Kenneth Wright L, Oncogene 2002 21 2000 2008 10.1038/sj.onc.1205260 11960372 (Pubitemid 34270888)
22. Stat3 mediates myeloid cell dependent tumor angiogenesis in mice. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H, J Clin Invest 2008 118 3367 3377 10.1172/JCI35213 18776941
23. Regulation of the IL-23 and IL-12 balance by Stat3 signaling the tumor microenvironment. Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T, Drake C, Pardoll D, Yu H, Cancer Cell 2009 15 114 123 10.1016/j.ccr.2008.12.018 19185846
24. IL-17 can promote tumor growth through an IL-6/Stat3 signaling pathway. Wang L, Yi T, Kortylewski M, Pardoll D, Zeng D, Yu H, J Exp Med 2009 206 1457 1464 10.1084/jem.20090207 19564351
25. A critical role for Stat3 signaling in immune tolerance. Cheng F, Wang HW, Cuenca A, Huang M, Ghansah T, Brayer J, Kerr WG, Takeda K, Akira S, Schoenberger SP, Yu H, Jove R, Sotomayor EM, Immunity 2003 19 425 436 10.1016/S1074-7613(03)00232-2 14499117 (Pubitemid 37153418)
26. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Yu H, Kortylewski M, Pardoll D, Nature Rev Immunol 2007 7 41 51 10.1038/nri1995 (Pubitemid 46020826)
27. Generation of diffuse large B cell lymphoma-associated antigen-specific V6/V13+T cells by TCR gene transfer. Yin Q, Zha X, Yang L, Chen S, Zhou Y, Wu X, Li Y, J Hematol Oncol 2011 4 2 9 10.1186/1756-8722-4-2 21223579
28. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Haura E B, Turkson J, Jove R, Nature Clin Pract Oncol 2005 2 315 324 (Pubitemid 40903176)
29. Cancer-related inflammation. Mantovani A, Allavena P, Sica A, Balkwill F, Nature 2008 454 436 444 10.1038/nature07205 18650914